Production of Several batches of SalMet-Vec® products successfully completed at Guangzhou Sinogen Pharmaceutical’s cGMP manufacturing facility.

Guangzhou, China, Sep.16, 2022, Guangzhou Sinogen Pharmaceutical’s(“Sinogen”) is a biopharmaceutical company committed to the development and production of innovative biological anti-tumor drugs to meet the needs of the global cancer treatment market. The company is located in Huangpu District, Guangzhou, and its manufacturing facility that complies with the current Good Manufacturing Practice (cGMP) has successfully completed the GMP production of several clinical batches of SalMet-Vec^® products, and all batches of products have been tested to meet the requirements of relevant quality standards and successfully released.

The oncolytic bacteria SalMet-Vec^® is the world's first biological product with tumor targeted amino acid metabolism regulation. After years of research, Sinogen Pharmaceutical has successfully built a variety of technical platforms, including: the technical platform for the industrialization of oncolytic bacteria, the technical platform for innovative tumor targeting drugs, the technical platform for the evaluation of the internal and external pharmacodynamics of anticancer drugs and the technical platform for the research of the targeting mechanism of oncolytic bacteria. At present, the company is rapidly improving the capacity of independent large-scale production and quality testing of SalMet-Vec^®  products in order to meet the needs of clinical trials and future commercial drugs.

Sinogen Pharmaceutica’s cGMP manufacturing facility has successfully completed the production of the first clinical batch of SalMet-Vec^® products in the first half of 2022, and has successfully transported this batch of products to the United States for clinical trial uses. Today, the stable production and release of multiple clinical batches of SalMet-Vec^® products marks that the company has the capacity to scale up the production of bacterial carrier genetic engineering anti-tumor drugs and can independently produce and supply bacterial carrier genetic engineering drugs in the future.

The company will accelerate the multi center registered clinical trials (intravenous and intratumoral) of SalMet-Vec^® for the treatment of broad-spectrum solid tumors, which are being carried out in the United States and Taiwan, China, and strive to provide more effective new therapeutic drugs for patients with malignant tumors worldwide as soon as possible.